HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
The Tasian Laboratory’s translational research program aims to develop targeted therapeutic strategies for high-risk childhood leukemias. One major research focus is the characterization of leukemia-associated intracellular signal transduction networks and preclinical testing of kinase inhibitors in genetic subtypes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). A second major focus is preclinical testing of chimeric antigen receptor (CAR) T cell immunotherapies in childhood AML and ALL.
In addition, Dr. Tasian and her research team conduct bench-to-bedside early-phase clinical trials of kinase inhibitors and CAR T cell immunotherapies for children with high-risk leukemias through the Children’s Oncology Group (COG) and other consortia. Many of these trials have directly resulted from preclinical studies conducted by the laboratory and its collaborators. The Tasian Lab also conducts bedside-back-to-bench studies for several clinical trials to measure patients’ molecular responses to these new targeted therapies.
- Characterization of kinase signaling and preclinical testing of kinase inhibitors in Philadelphia chromosome-like (Ph-like) ALL
- Characterization of kinase signaling and preclinical testing of kinase inhibitors in infant ALL
- Preclinical testing of targeted therapies in myeloid leukemias (AML and JMML)
- Preclinical testing of chimeric antigen receptor (CAR) T cell immunotherapies in high-risk genetic subsets of ALL and AML
- Correlative biology studies for early phase clinical trials of targeted therapies in children with relapsed leukemias
Sarah K. Tasian, MD
Dr. Tasian's research centers on the bench-to-bedside investigation of precision medicine therapies for high-risk childhood leukemias.